Skip to main content
Finanzoo GmbH Finanzoo GmbH

Array BioPharma Value Stock - Dividend - Research Selection

Array biopharma

ISIN: US04269X1054 , WKN: 580564
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company\'s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


ARRAY Technologies Names Darin Green as Chief Revenue Officer for North America

2025-01-06
Green brings extensive global experience in renewables, strategy, and cross-functional revenue leadership Darin Green ARRAY Names Darin Green as Chief Revenue Officer North America ALBUQUERQUE, N.M., Jan. 06, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading provider of tracker solutions and services for utility-scale solar energy projects, has named Darin Green as its chief revenue officer for North America, effective today, January 6. Green will r
Yahoo

Why Array Technologies (ARRY) Is Among the Best Renewable Energy Stocks to Buy?

2024-12-31
We recently published a list of the 11 Best Renewable Energy Stocks To Buy Now. In this article, we are going to take a look at where Array Technologies, Inc. (NASDAQ:ARRY) stands against the other best renewable energy stocks to buy now. The future of President Joe Biden’s landmark climate legislation, the Inflation Reduction Act […]
Yahoo

Heritage Distilling Names Michael P. Carrosino as Chief Financial Officer

2024-12-31
Veteran finance executive with more than 40 years’ experience to lead Heritage’s financial operations and manage capital market transactionsGIG HARBOR, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Heritage Distilling Company, Inc. (NASDAQ: CASK) ("HDC" or "Heritage" or "The Company,") a leading craft distiller of innovative premium brands, announced the appointment of Michael P. Carrosino as its Chief Financial Officer (CFO). A veteran finance executive with over 40 years’ experience, Mr. Carrosino
Yahoo

Is Array Technologies (ARRY) One of the Best Solar Energy Stocks to Buy Now?

2024-12-24
We recently published a list of 10 Best Solar Energy Stocks To Buy Now. In this article, we are going to look at where Array Technologies, Inc. (NASDAQ:ARRY) stands against other best solar energy stocks to buy now. During Joe Biden’s presidency, the U.S. solar industry experienced a significant boost, primarily driven by the Inflation […]
Yahoo

Heritage Distilling Company Strengthens Senior Leadership Team with Key Appointments to Accelerate Next Stage of Growth and Innovation

2024-12-19
Expands Executive Team and Board of Directors with Former Starbucks COO Troy Alstead as a Director and Andrew Varga as a Director and Strategic Consultant - Chief Revenue OfficerGIG HARBOR, Wash., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Heritage Distilling Company, Inc. (“HDC” or “Heritage”) (Nasdaq: CASK), a leading craft distiller of innovative premium brands, announced today two key appointments to its executive leadership and Board of Directors. These include Troy Alstead, a seasoned global execut
Yahoo

Is Array Technologies (ARRY) the Best Alternative Fuel Stock to Buy According to Hedge Funds?

2024-12-11
We recently published a list of 10 Best Alternative Fuel Stocks To Buy According to Hedge Funds. In this article, we are going to look at where Array Technologies, Inc. (NASDAQ:ARRY) stands against other best alternative fuel stocks to buy according to hedge funds. The alternative fuel and renewable energy industry is currently one of […]
Yahoo

Nextracker And Array Technologies: Both Look Promising, But One Is Clearly Best-In-Class

2024-12-10
Nextracker (NXT) and Array Technologies (ARRY) dominate the solar tracking market. Find out which one is a better buy.
SeekingAlpha

Tax-Loss Stocks To Sell Before Everyone Else Does

2024-12-09
Prepare for tax-loss selling at year-end by considering selling underperforming stocks like Celanese, Walgreens, and Intel. Explore more details here.
SeekingAlpha

Why Array Technologies (ARRY) Is Among the Best Wind Power and Solar Stocks to Invest in Now

2024-12-07
We recently published a list of 10 Best Wind Power and Solar Stocks To Invest In Now. In this article, we are going to take a look at where Array Technologies, Inc. (NASDAQ:ARRY) stands against other best wind power and stocks to invest in now. According to a report by the World Economic Forum published […]
Yahoo

ARRAY Technologies and RP Surpass 6GW of Solar Power Deployed

2024-12-04
ARRAY and RP’s long-time partnership surpasses 6GW of solar powerALBUQUERQUE, N.M., Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a global leader in solar tracker solutions, announced today that it has deployed more than 6GW of solar projects in North America through its partnership with RP Construction Services (RP), a leading value-added distributor of solar construction materials. The ARRAY and RP teams have worked together since 2009 to serve
Yahoo